Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM).
J. J. Vredenburgh
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
A. Desjardins
No relevant relationships to disclose
D. A. Reardon
Consultant or Advisory Role - Roche/Genentech; Schering-Plough
Honoraria - Roche/Genentech; Schering-Plough
K. Peters
No relevant relationships to disclose
J. Kirkpatrick
Honoraria - BrainLAB; Varian Medical Systems
Research Funding - Genentech; Varian Medical Systems
A. D. Coan
No relevant relationships to disclose
L. Bailey
No relevant relationships to disclose
D. Janney
No relevant relationships to disclose
C. Lu
Employment or Leadership Position - Duke University Medical Center
H. S. Friedman
Consultant or Advisory Role - Genentech
Honoraria - Roche/Genentech